Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HYDROCHLORIDE vs CIN-QUIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Treatment of life-threatening ventricular arrhythmias,Atrial fibrillation,Atrial flutter,Paroxysmal supraventricular tachycardia
Treatment of atrial fibrillation and flutter,Paroxysmal supraventricular tachycardia,Ventricular arrhythmias,Maintenance of sinus rhythm after cardioversion
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., Cr Cl <30 m L/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Hepatic acetylation via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); CYP2D6 minor pathway.
Metabolized primarily by CYP3A4 to active metabolites (3-hydroxyquinidine and quinidine-N-oxide).
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
~15-20% bound to serum albumin and alpha-1-acid glycoprotein; low binding minimizes displacement interactions.
Approximately 70-80% bound, primarily to alpha-1-acid glycoprotein and, to a lesser extent, albumin.
Vd: 1.5-2.5 L/kg (total body water); extensive tissue distribution (e.g., heart, liver, kidneys); clinical meaning: large Vd indicates substantial extravascular distribution, requiring loading doses for rapid therapeutic effect.
Apparent volume of distribution (Vd) is 1.5-2.5 L/kg, indicating extensive tissue distribution.
Oral: 75-95% (immediate-release); IM: 100%; sustained-release oral: ~90% (relative to immediate-release).
Oral bioavailability is approximately 80% in healthy subjects; may be reduced in patients with malaria due to impaired absorption.
Cr Cl 10-50 m L/min: administer every 6-12 hours. Cr Cl <10 m L/min: administer every 8-24 hours. For IV: reduce maintenance infusion rate proportional to Cr Cl.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <10 m L/min), reduce dose by one-third to one-half (e.g., 324 mg every 8 hours) and monitor for toxicity.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: avoid use or reduce dose by 50-75% with monitoring.
No specific guidelines for Child-Pugh classification; use with caution in severe hepatic impairment (Child-Pugh C) and consider dose reduction by 50% based on clinical response and monitoring of serum levels.
Oral: 15-50 mg/kg/day divided every 3-6 hours. IV: Loading dose 15-18 mg/kg; maintenance 20-80 mcg/kg/min. Maximum: 100 mg/kg/day.
For malaria: quinine sulfate 10 mg/kg (base) orally every 8 hours for 7 days (maximum 650 mg/dose) in combination with a second agent.
Start with lower doses (e.g., 250 mg oral every 6 hours) due to age-related renal decline. Monitor for hypotension and toxicity. Adjust based on Cr Cl.
No specific dose adjustments recommended, but start at lower end of dosing range (e.g., 324 mg every 8 hours) due to age-related renal function decline and increased risk of QT prolongation.
May cause severe blood dyscrasias (e.g., agranulocytosis, neutropenia, thrombocytopenia) and drug-induced lupus erythematosus.
Quinidine has been associated with thrombocytopenic purpura and may exacerbate arrhythmias (proarrhythmia). It should be used with caution in patients with severe heart disease or preexisting arrhythmias.
Monitor CBC regularly; discontinue if blood dyscrasias occur. Prolonged QT interval risk; caution with other QT-prolonging drugs. May exacerbate heart failure or hypotension. Reduce dose in renal impairment.
May cause QT prolongation and torsades de pointes, especially in patients with hypokalemia, hypomagnesemia, or bradycardia,Cinchonism (tinnitus, hearing loss, blurred vision, nausea) may occur at high doses,Hepatic toxicity and hypersensitivity reactions (including thrombocytopenia),Monitor serum potassium and magnesium levels,Avoid use with other drugs that prolong QT interval
Complete heart block, second-degree AV block, torsade de pointes, systemic lupus erythematosus, hypersensitivity to procainamide or procaine.
Hypersensitivity to quinidine or cinchona alkaloids,Complete AV block without pacemaker,Myasthenia gravis,Digitalis toxicity,History of drug-induced torsades de pointes or QT prolongation
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes) as hyperkalemia may increase proarrhythmic risk. Alcohol may exacerbate hypotension and cardiac effects.
Avoid grapefruit and grapefruit juice (increases quinidine exposure). Limit caffeine intake as quinidine may enhance its effects. Maintain adequate potassium and magnesium intake; hypokalemia and hypomagnesemia increase arrhythmia risk.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placental perfusion; use only if clearly needed. Risk of neonatal arrhythmias if used near term.
CIN-QUIN (quinine) is contraindicated in pregnancy due to teratogenicity. First trimester: risk of congenital malformations (e.g., auditory nerve hypoplasia, limb defects). Second and third trimesters: may cause fetal hypoxia and hypoglycemia; avoid use for malaria prophylaxis. Only in severe falciparum malaria when no alternative exists.
Present in breast milk in low concentrations; M/P ratio approximately 0.4-0.6. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for bradycardia or hypotension.
Quinine is excreted into breast milk in small amounts. M/P ratio approximately 0.2-0.5. Limited data suggest low risk to infant; however, monitor for signs of cinchonism (e.g., fever, rash, restlessness).
No specific dose adjustments recommended; however, increased volume of distribution and renal clearance in pregnancy may require higher doses or more frequent administration to maintain therapeutic levels. Monitor drug levels closely.
Pregnancy increases clearance and volume of distribution of quinine; dose adjustments are not well-defined. For severe malaria, standard dosing (600 mg oral quinine sulfate every 8 hours for 7 days) is used, but therapeutic drug monitoring is recommended.
Procainamide is a Class Ia antiarrhythmic. Monitor for lupus-like syndrome (arthralgias, rash) especially in slow acetylators; screen with ANA titer. Torsades de Pointes risk; monitor QTc. Maintain serum potassium >4.0 m Eq/L. Avoid in myasthenia gravis. Adjust dose in renal impairment.
Cin-Quin is a brand of quinidine, a class Ia antiarrhythmic. Monitor QTc interval; risk of torsades de pointes. Avoid in patients with myasthenia gravis due to neuromuscular blocking effects. Use with caution in hepatic impairment. Can cause cinchonism (tinnitus, headache, nausea).
Take exactly as prescribed; do not skip doses.,Report any joint pain, rash, fever, or unexplained bruising immediately.,Avoid driving if you experience dizziness or lightheadedness.,Notify your doctor if you have new or worsening shortness of breath or chest pain.,Do not stop taking abruptly; this may cause a serious irregular heartbeat.
Take exactly as prescribed; do not skip doses or double up.,Report any rapid or irregular heartbeat, fainting, or severe dizziness.,Avoid grapefruit juice as it can increase quinidine levels.,Do not use with over-the-counter products containing quinine or quinidine.,Tell your doctor if you have liver disease, myasthenia gravis, or low potassium/magnesium.,Quinidine can cause diarrhea; contact your doctor if persistent.,You may experience ringing in the ears or blurred vision; notify your prescriber.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HYDROCHLORIDE vs CIN-QUIN, answered by our medical review team.
PROCAINAMIDE HYDROCHLORIDE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.. CIN-QUIN is a Antiarrhythmic (Class Ia) that works by Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HYDROCHLORIDE and CIN-QUIN depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HYDROCHLORIDE is: Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.. The standard adult dose of CIN-QUIN is: Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HYDROCHLORIDE and CIN-QUIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HYDROCHLORIDE is classified as Category A/B. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placent. CIN-QUIN is classified as Category C. CIN-QUIN (quinine) is contraindicated in pregnancy due to teratogenicity. First trimester: risk of congenital malformations (e.g., auditory nerve hypoplasia, limb defects). Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.